Blood Cancer Clinical Trial
Official title:
Predictive Markers of Response and Toxicity in Patients With a Haematological Malignancy Treated With Immunotherapy.
Immunotherapies have substantially improved the prognosis of patients with haematological malignancies. While clinical trial data suggest durable complete response rates, markers associated with non-response to treatment are still poorly described. The identification of predictive markers using demographic, physiologic, biologic, immunologic data as well as patients' treatment history, might enable the optimization of therapeutic sequences and the reduction of treatment toxicity. This study aim to assess markers of toxicity and response following an immunotherapy in patients with a haematological malignancy using real life data. It will allow the development of clinical and therapeutic benchmarks to guide medical decisions in relation to the therapeutic strategies to be implemented for patients benefiting from real-life conditions, in addition to the results obtained in randomized studies.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
| Not yet recruiting |
NCT06455592 -
Effect of APA on Sleep Quality in Children With Cancer From 5 to 16 Years
|
N/A | |
| Completed |
NCT03654404 -
A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients
|
N/A | |
| Recruiting |
NCT06116032 -
Immune Profiling for Cancer Immunotherapy Response
|
||
| Recruiting |
NCT04955938 -
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
|
Phase 1 | |
| Recruiting |
NCT06119685 -
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05391490 -
Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT06469307 -
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
|
||
| Recruiting |
NCT05709522 -
Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients
|
||
| Completed |
NCT00186225 -
Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors
|
N/A | |
| Active, not recruiting |
NCT05147311 -
Positive Psychology Intervention In HSCT
|
N/A | |
| Recruiting |
NCT04372524 -
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
|
||
| Completed |
NCT01957579 -
A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
|
Phase 1 | |
| Completed |
NCT00185640 -
Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies
|
Phase 2 | |
| Withdrawn |
NCT04390542 -
Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy
|
N/A | |
| Completed |
NCT04419623 -
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
|
Phase 1 | |
| Recruiting |
NCT04806295 -
The Leukemia and Lymphoma Society (LLS) National Research Registry
|
||
| Recruiting |
NCT05873205 -
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
|
Phase 2 | |
| Completed |
NCT00962494 -
Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors
|
Phase 2 | |
| Completed |
NCT00185796 -
TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
|
Phase 2 |